iShares Global Healthcare

Most Recent

  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca and Its Oncology Segment’s Growth in 2Q16

    AstraZeneca’s (AZN) oncology segment is another key focus area. The segment’s contribution increased to more than 15% in 2Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What to Expect from Pfizer’s 2Q16 Earnings

    In Pfizer’s 2Q16 results, analysts expect to see EPS (or earnings-per-share) of $0.62 and revenues of ~$13.0 billion for 2Q16. The company has surpassed Wall Street analysts’ estimates for EPS over the last few quarters.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca Is Taking Steps to Improve Its Position in Oncology

    During the last quarter, the oncology segment’s contribution to AstraZeneca (AZN) increased to over 15%. AZN’s key products for oncology are Zoladex, Faslodex, Iressa, and the new drug Tagrisso.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Novartis Will Report Its 4Q15 Earnings on January 27

    Novartis is set to release its 4Q15 and full-year 2015 earnings on January 27, 2016. Analysts estimate an EPS of $1.32 for 4Q15.

    By Mike Benson
  • uploads///Chart  Rev EPS
    Company & Industry Overviews

    What’s Gilead Sciences’ Valuation?

    Gilead’s stock price has risen ~8.9% in the last 12 months. Wall Street analysts estimate that the stock price will fall ~4.5% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca’s Key Focus: Oncology

    AstraZeneca’s (AZN) key focus is its oncology segment. The segment’s contribution increased to more than 12% in 1Q16. Its key products include Zoladex, Faslodex, and Iressa.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Other Drugs for Non-small Cell Lung Cancer

    Approximately 85% of all lung cancers in the United States are non-small cell lung cancers, and 10% to 15% of these are EGFR mutation-positive.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Envision Healthcare to Be Acquired by KKR

    On June 11, Envision entered into a definitive acquisition agreement with KKR.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Eli Lilly’s 4Q17 Estimates: Revenue Growth Expected

    Wall Street analysts estimate an ~3.1% increase in Eli Lilly & Co.’s (LLY) 4Q17 revenues to ~$5.9 billion.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analysts’ Estimates for Pfizer’s 4Q17 Earnings

    For 4Q17, Wall Street analysts expect Pfizer to report an EPS (earnings per share) of $0.56 on revenues of $13.72 billion.

    By Mike Benson
  • uploads///Chart  SWR
    Company & Industry Overviews

    Merck & Co.’s Business Segments and Performance in 3Q17

    Merck’s (MRK) Pharmaceuticals segment reported revenues of $9.2 billion in 3Q17, contributing more than 88% to Merck’s total revenues.

    By Mike Benson
  • uploads///Chart  ICR
    Company & Industry Overviews

    Assessing Merck’s Immunology and Cardiovascular Franchise in 2Q17

    Merck’s (MRK) Immunology franchise includes two drugs, Remicade and Simponi.

    By Mike Benson
  • uploads///Chart  CVMD
    Company & Industry Overviews

    Performance of AstraZeneca’s CVMD Segment in 2Q17

    The Cardiovascular and Metabolic Disease (or CVMD segment) contributed ~35.1% of total revenues for AstraZeneca (AZN) in 2Q17.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Bristol-Myers Squibb’s Revenues in 2Q17

    Bristol-Myers Squibb (BMY) surpassed Wall Street analysts’ estimate for 2Q17 revenues, reporting $5.14 billion compared to the estimate of $5.09 billion.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Inside Incyte’s Jakafi Performance in 2Q17

    Incyte’s Jakafi is the only FDA-approved drug for the treatment of myelofibrosis and polycythemia vera.

    By Mike Benson
  • uploads///Chart  EPS
    Earnings Report

    AstraZeneca’s 2Q17 Earnings: Analysts’ Estimates

    AstraZeneca (AZN) is one of the largest pharmaceutical companies by revenue. The company operates in over 100 countries and deals with primary care and specialty care medicines.

    By Mike Benson
  • uploads///Chart  Developments
    Earnings Report

    Major Developments for Johnson and Johnson

    Major developments As discussed earlier, Johnson & Johnson’s (JNJ) 2Q17 performance was positive across all three of its segments. Let’s look at major developments for the company in 2Q17. Pharmaceuticals On July 13, 2017, the FDA approved Tremfya (guselkumab) for the treatment of patients with moderate to severe plaque psoriasis. On June 28, 2017, the […]

    By Mike Benson
  • uploads///Chart  Ratings
    Earnings Report

    Analyst Ratings and Recommendations for Novartis Post 2Q17

    For 2Q17, analysts are estimating EPS of $1.18 for Novartis (NVS) on revenues of $12.3 billion.

    By Mike Benson
  • uploads///Chart  International
    Company & Industry Overviews

    Inside Allergan’s International Business

    Allergan’s International segment reported revenues of $737.3 million for 1Q17, which was 9.5% higher than the $673.3 million it reported in 1Q16.

    By Mike Benson
  • uploads///Chart  CELG
    Miscellaneous

    How Celgene Stock Performed in 2Q17

    Celgene (CELG) stock has risen ~6.1% in 2Q17, while it has risen ~14.0% year-to-date as of July 7, 2017.

    By Mike Benson
  • uploads///Chart  Diabetes
    Company & Industry Overviews

    Performance of Merck’s Diabetes Drugs in 1Q17

    In 1Q17, Januvia and Janumet reported combined revenues of ~$1.3 billion.

    By Mike Benson
  • uploads///Chart  Margin
    Company & Industry Overviews

    Changes in Bristol-Myers Squibb’s Profitability 1Q17

    Bristol-Myers reported a net profit of ~$1.57 billion in 1Q17—compared to $1.19 billion in 1Q16. Analysts expect a net profit of $1.18 billion during 2Q16.

    By Mike Benson
  • uploads///Chart  Animal
    Company & Industry Overviews

    Performance of Elanco in 1Q17

    Elanco’s 1Q17 revenues include revenues from the acquired Novartis Animal Health products. The US Animal Health franchise reported growth of 5% in its 1Q17 revenues to $413.8 million.

    By Mike Benson
  • uploads///Chart  CVMD
    Company & Industry Overviews

    Exploring the Performance of AstraZeneca’s CVMD Segment in 1Q17

    The Cardiovascular and Metabolic Disease (or CVMD) segment contributed ~33% of AstraZeneca’s (AZN) total revenue in 1Q17.

    By Mike Benson
  • uploads///Chart  Segment
    Company & Industry Overviews

    Johnson & Johnson’s Business Segments in 1Q17

    Johnson & Johnson’s business includes three segments: Pharmaceuticals, Consumer, and Medical Devices.

    By Mike Benson
  • uploads///Chart  SWR
    Company & Industry Overviews

    AstraZeneca’s Segment-by-Segment Performance in 1Q17

    AstraZeneca’s (AZN) business is separated into four segments: Respiratory, Cardiovascular and Metabolic Diseases (or CVMD), Oncology, and Other.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Performance of Merck’s Animal Health Segment in 1Q17

    Merck’s (MRK) Animal Health segment operates in more than 140 countries worldwide. Global sales in 1Q17 were $939.0 million, a 13.0% rise from 1Q16.

    By Mike Benson
  • uploads///Chart  EPS
    Earnings Report

    Allergan’s 1Q17 Earnings: Analysts’ Estimates

    Allergan (AGN) is set to release its 1Q17 earnings on May 9, 2017. Analysts’ estimates show EPS at $3.30 on revenues of $3.53 billion for 1Q17.

    By Mike Benson
  • uploads///Chart  Rev Brkup
    Earnings Report

    Pfizer’s Geographical Performance in 1Q17

    To better understand the factors affecting growth, let’s take a look at Pfizer’s performance in US markets and beyond in 1Q17.

    By Mike Benson
  • uploads///Chart  CH
    Earnings Report

    GlaxoSmithKline’s 1Q17 Estimates: Consumer Healthcare

    For the European markets, GSK’s revenues are expected to grow in 1Q17, mainly due to increase in sales of wellness products like Voltaren and the Sensodyne products portfolio.

    By Mike Benson
  • uploads///Chart  EPS
    Earnings Report

    What Analysts Expect of Bristol-Myers Squibb’s 1Q17 Earnings

    Bristol-Myers Squibb is set to release its 1Q17 earnings on April 27, 2017. Analysts expect EPS (earnings per share) of $0.74 and revenue of $4.7 billion for the company in 1Q17.

    By Mike Benson
  • uploads///Chart  Sandoz
    Earnings Report

    Novartis’s 1Q17 Estimates for Sandoz

    Sandoz’s revenues are expected to rise in 1Q17 following an increased demand for biopharmaceuticals such as biosimilars and Glatopa.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Revenue Estimates: Expect Growth!

    The Pharmaceuticals segment contributes ~46.5% of Johnson & Johnson’s total revenues. The segment is expected to report operational growth.

    By Mike Benson
  • uploads///Chart  GILD
    Miscellaneous

    Examining Gilead Sciences’ 1Q17 Performance

    Gilead’s stock price fell ~12.6% in 1Q17. On April 6, 2017, its stock price had fallen 7.2% year-to-date (or YTD).

    By Mike Benson
  • uploads///Chart  JNJ
    Miscellaneous

    Assessing Johnson & Johnson’s 1Q17 Performance

    Johnson & Johnson (JNJ) is one of the largest pharmaceutical and healthcare companies. It supplies its products to over 200 countries worldwide.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Must-Know Corporate and Pipeline Developments for Pfizer

    On February 17, 2017, Pfizer and Celltrion Healthcare released data for a randomized 54-week clinical trial that met its primary endpoint.

    By Mike Benson
  • uploads///Chart  NewProducts
    Company & Industry Overviews

    How Eli Lilly’s New Products Performed in 2016

    Eli Lilly (LLY) has launched various products under different franchises. A few of these new products include Portrazza, Cyramza, Basaglar, Jardiance, Taltz, and Trulicity.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Gilead’s Other Products Fared in 2016

    The oncology portfolio includes the drug Zydelig, which is used in combination with rituximab for the treatment of chronic lymphocytic leukemia (or CLL).

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Strong Performance of AstraZeneca’s Brilinta and Farxiga in 2016

    The Cardiovascular and Metabolic Disease segment is the largest contributor of revenues for AstraZeneca (AZN). The CVMD segment contributed nearly 35.2% to AZN’s total revenues in 2016.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Valuation after Its 4Q16 Earnings Release

    Pfizer was trading at a forward PE multiple of ~13.0x on February 23, 2017, compared to the industry average of ~16.1x.

    By Mike Benson
  • uploads///Chart  Endo
    Company & Industry Overviews

    Eli Lilly & Co.’s Endocrine Franchise

    Eli Lilly’s (LLY) Humulin portfolio consists of concentrated insulin products used to lower the blood sugar levels in patients with type 1 and type 2 diabetes mellitus.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analyzing Merck & Co.’s Revenue Estimates in 4Q16

    Analysts expect Merck & Co.’s (MRK) revenues for 4Q16 to be ~$10,216 million—nearly flat compared to revenues of $10,215 million in 4Q15.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Opdivo: Bristol-Myers Squibb’s Blockbuster Oncology Drug

    Opdivo reported revenues of $1.3 billion in 4Q16 compared to $475.0 million in 4Q15.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s 4Q16 Performance by Business Segment

    Johnson & Johnson’s overall business is classified into three business segments: Pharmaceuticals, Consumer, and Medical Devices.

    By Mike Benson
  • uploads///Chart  Neuro
    Earnings Report

    How Will Eli Lilly’s Neuroscience Franchise Fare in 4Q16?

    The neuroscience franchise contributes over ~13% of Lilly’s total revenues. Key drugs in this segment include Zyprexa, Cymbalta, and Strattera.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Novartis’s 4Q16 Estimates: How Could Sandoz Perform?

    Sandoz contributes nearly 20% to Novartis’s (BVS) total revenues.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Why Johnson & Johnson’s 4Q16 Revenues Could Grow

    Analysts expect a growth of 2.5% in Johnson & Johnson’s (JNJ) 4Q16 revenues to ~$18.3 billion, following an increase in sales of its blockbuster drugs including Remicade, Stelara, Olysio, and Zytiga.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Exploring GlaxoSmithKline’s Business Segments

    GlaxoSmithKline’s (GSK) business is divided into three business segments: Pharmaceuticals, Vaccines, and Consumer Health.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    GlaxoSmithKline’s Revenue Trend

    GlaxoSmithKline reported a rise of 23% in its 3Q16 revenue. The company met Wall Street analysts’ consensus 3Q16 estimates for revenue and earnings per share.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Does Johnson & Johnson’s Valuation Compare to Its Peers?

    According to its December 7, 2016, data, Johnson & Johnson’s (JNJ) stock has risen more than 8.5% over the last 12 months. Analysts estimate that the stock has the potential to return ~12.7% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Inside Merck’s Business Segment-Wise Performance

    Merck (MRK) reported a growth of 5% in its revenues of ~$10.5 billion in 3Q16. The company reported an operational growth of 6% during 3Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s Valuation Compared to Its Peers

    Allergan’s stock value fell more than 40% over the last 12 months. Analysts estimate that the stock could to return ~39.5% over the next 12 months.

    By Mike Benson
  • uploads///Chart  Neuro
    Company & Industry Overviews

    Inside Eli Lilly’s Neuroscience Franchise

    Another key Eli Lilly franchise in the Human Pharmaceuticals segment is neuroscience. Key drugs in this franchise include Zyprexa, Cymbalta, and Strattera.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Can We Expect of Pfizer’s 3Q16 Earnings?

    Pfizer is set to release its 3Q16 earnings on November 1. Analysts estimate EPS of $0.62 for 3Q16. PFE’s stock has fallen ~4% in the past 12 months.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Novartis’s 3Q16 Estimates: How Has Sandoz Performed?

    Sandoz, Novartis’s (NVS) generics arm, develops, manufactures, distributes, and sells prescription drugs that aren’t protected by patents.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Word on the Street about Merck’s Animal Health Segment

    Merck & Co.’s (MRK) Animal Health segment operates in more than 140 countries worldwide. Global sales for the segment are expected to rise to $915 million in 3Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Eli Lilly and Co.’s 3Q16 Estimates: Neuroscience Franchise

    Another franchise from Eli Lilly and Co.’s (LLY) human pharmaceuticals segment is the neuroscience franchise.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Pharmaceuticals Segment: 3Q16 Estimates

    Johnson & Johnson’s (JNJ) Pharmaceuticals segment is comprised of immunology, infectious disease, neuroscience, oncology, and cardiovascular and metabolics.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Roche Sees Soaring Revenue from Its Bladder Cancer Treatment

    Roche’s (RHHBY) Tecentriq is a programmed death ligand-1 (or PD-L1) inhibitor that is already approved by the FDA for the treatment of locally advanced or metastatic bladder cancer.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Investors Can Glean from GlaxoSmithKline’s Revenue Trend

    GlaxoSmithKline (GSK) reported a growth of 10.9% to 6.5 billion pounds in its 2Q16 revenues.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Is Johnson & Johnson’s Valuation High Compared to Its Peers?

    The two best valuation multiples used for valuing companies like Johnson & Johnson are the forward PE and EV-to-EBITDA multiples due to visible earnings.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca’s Recent Product Developments

    AstraZeneca (AZN) has four drugs that recently received approvals from regulatory authorities. Four other drugs recently received regulatory designations.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Crestor Weakened AstraZeneca’s CVMD Segment in 2Q16

    Crestor, which is used to reduce cholesterol and triglycerides in the blood, contributed ~16.5% of AstraZeneca’s total 2Q16 revenues.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Remicade Is Driving Down Merck’s Immunology Franchise

    Remicade is one of the blockbuster drugs for Merck and Co. (MRK). It is one of the top-selling drugs for the treatment of inflammatory disorders.

    By Mike Benson
  • uploads///Chart  Neuroscience
    Earnings Report

    Revenues from Eli Lilly’s Cymbalta Are Depressed Internationally

    Another franchise from Eli Lilly’s (LLY) human pharmaceuticals segment is the neuroscience franchise.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Understanding Lilly’s New Product Expectations for 2Q16

    Eli Lilly’s newest products include Portrazza, Cyramza, Basaglar, Jardiance, and Trulicity.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Inside Lilly’s 2Q16 Estimates for Its Neuroscience Franchise

    Another franchise in Eli Lilly’s Human Pharmaceuticals segment is the neuroscience franchise, which contributes ~13% of Lilly’s total revenues.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Why AbbVie Continues to Explore Imbruvica for Diffuse Large B-Cell Lymphoma

    AbbVie hopes to position Imbruvica as a therapy for multiple indications: follicular lymphoma, solid tumor, and diffuse large B-cell lymphoma, among others.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    What’s AstraZeneca’s Largest Revenue Contributor?

    AstraZeneca’s (AZN) cardiovascular and metabolic disease (or CVMD) segment is the company’s largest revenue contributor. It contributed nearly 37.5% of total revenues in 1Q16.

    By Mike Benson
  • uploads///RD expenses
    Company & Industry Overviews

    Analyzing Intuitive Surgical’s R&D Strategy and Innovations

    Intuitive Surgical is continuously enhancing its product offerings, enabling more efficient procedures through internal research and development (or R&D).

    By Sarah Collins
  • uploads///A US GDP
    Company & Industry Overviews

    Recovery for the Manufacturing Sector Is Not Yet in Sight

    Manufacturing growth as measured by the ISM (Institute for Supply Management) index ended lower for the fifth consecutive month at the end of February. However, it rose in March

    By Russ Koesterich, CFA
  • uploads///bridging study
    Company & Industry Overviews

    What Is a Bridging Study?

    A bridging study on a drug is an additional study performed in a new region to provide clinical data on safety, efficacy, dosage, and dose regimen.

    By Jillian Dabney
  • uploads///New drug development and approval
    Company & Industry Overviews

    What’s the Drug Approval Process in Japan?

    The drug approval process in Japan includes a sequence of non-clinical studies, clinical studies followed by approval review, and post-marketing surveillance.

    By Jillian Dabney
  • uploads///hip market share
    Company & Industry Overviews

    Zimmer Biomet’s Competition in the Hip Implant Market

    Zimmer Biomet (ZBH) is one of the leading hip implant providers in the United States, with approximately 31% market share.

    By Sarah Collins
  • uploads/// World population
    Company & Industry Overviews

    How Structural Changes in the World Economy Affect Markets

    For the last few years, the world has been in the midst of a major demographic transition, which has affected the world economy. The aging population is one of the most visible global trends

    By Rick Rieder
  • uploads///specialty diagnostics
    Company & Industry Overviews

    Specialty Diagnostics Segment of Thermo Fisher Scientific

    A leading provider of diagnostic products and services, Thermo Fisher Scientific (TMO) has witnessed strong recurring revenues and high margins in the Specialty Diagnostics Segment over the years.

    By Sarah Collins
  • uploads///life sciences solutions
    Company & Industry Overviews

    The Life Sciences Solutions Segment of Thermo Fisher Scientific

    Thermo Fisher Scientific’s Life Sciences Solutions segment earned revenues of ~$4.2 billion in 2014, representing organic growth of around 4%.

    By Sarah Collins
  • uploads///diagnostic
    Company & Industry Overviews

    A Rundown of Abbott Laboratories’ Diagnostic Products Segment

    Abbott Laboratories is one of the leading companies in the diagnostic products space in the United States, with sales of around $4.7 billion in 2014.

    By Sarah Collins
  • uploads///restorative therapies segmentation
    Company & Industry Overviews

    Analyzing Medtronic’s Restorative Therapies Group Segment

    Medtronic’s Restorative Therapies Group’s net sales in fiscal 2015 reached ~$6.8 billion, which represents an increase of 4% over the prior fiscal year.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca’s Tagrisso Approved by FDA for Lung Cancer

    The FDA approved Tagrisso under an accelerated approval program that allows earlier approval of drugs for the treatment of serious diseases.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.